Sharon H. Giordano
About
Sharon H. Giordano is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Sharon H. Giordano has authored 408 papers receiving a total of 20.8k indexed citations (citations by other indexed papers that have themselves been cited), including 203 papers in Oncology, 135 papers in Cancer Research and 73 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sharon H. Giordano's work include Breast Cancer Treatment Studies (125 papers), Global Cancer Incidence and Screening (59 papers) and Economic and Financial Impacts of Cancer (46 papers). Sharon H. Giordano is often cited by papers focused on Breast Cancer Treatment Studies (125 papers), Global Cancer Incidence and Screening (59 papers) and Economic and Financial Impacts of Cancer (46 papers). Sharon H. Giordano collaborates with scholars based in United States, United Kingdom and Italy. Sharon H. Giordano's co-authors include Gabriel N. Hortobágyi, Thomas A. Buchholz, Aman U. Buzdar, James S. Goodwin, Mariana Chávez‐MacGregor, Benjamin D. Smith, Kristine Broglio, Ya‐Chen Tina Shih, Zhigang Duan and Debra A. Patt and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.
In The Last Decade
Sharon H. Giordano
383 papers receiving 20.3k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sharon H. Giordano United States | 76 | 10.8k | 7.4k | 4.1k | 3.3k | 3.1k | 408 | 20.8k | ||
| Hyman B. Muss United States | 84 | 17.2k 1.6× | 9.4k 1.3× | 5.7k 1.4× | 3.6k 1.1× | 2.3k 0.7× | 556 | 29.7k | ||
| William F. Anderson United States | 55 | 8.9k 0.8× | 4.6k 0.6× | 3.9k 1.0× | 3.1k 0.9× | 1.6k 0.5× | 134 | 21.6k | ||
| J.W.W. Coebergh Netherlands | 87 | 16.3k 1.5× | 4.5k 0.6× | 6.4k 1.6× | 1.9k 0.6× | 2.9k 0.9× | 520 | 30.6k | ||
| Mark R. Somerfield United States | 70 | 13.4k 1.2× | 6.9k 0.9× | 6.2k 1.5× | 1.9k 0.6× | 2.5k 0.8× | 141 | 27.5k | ||
| Alan S. Coates Australia | 76 | 14.4k 1.3× | 11.0k 1.5× | 4.3k 1.0× | 4.9k 1.5× | 1.4k 0.4× | 297 | 23.6k | ||
| Harold J. Burstein United States | 67 | 11.9k 1.1× | 7.1k 1.0× | 4.4k 1.1× | 2.3k 0.7× | 745 0.2× | 220 | 19.1k | ||
| Roger A’Hern United Kingdom | 75 | 9.4k 0.9× | 5.4k 0.7× | 5.2k 1.3× | 2.5k 0.8× | 1.1k 0.3× | 282 | 20.5k | ||
| Michael Friedländer Australia | 73 | 15.7k 1.5× | 4.6k 0.6× | 3.7k 0.9× | 5.2k 1.6× | 2.1k 0.7× | 493 | 27.5k | ||
| Antonio C. Wolff United States | 71 | 15.9k 1.5× | 10.7k 1.4× | 4.9k 1.2× | 1.9k 0.6× | 1.1k 0.3× | 360 | 24.8k | ||
| Lynn A. G. Ries United States | 56 | 13.0k 1.2× | 3.6k 0.5× | 6.6k 1.6× | 1.8k 0.6× | 3.1k 1.0× | 81 | 26.7k |
Countries citing papers authored by Sharon H. Giordano
Since
Specialization
Citations
This map shows the geographic impact of Sharon H. Giordano's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sharon H. Giordano with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sharon H. Giordano more than expected).
Fields of papers citing papers by Sharon H. Giordano
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Sharon H. Giordano. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sharon H. Giordano. The network helps show where Sharon H. Giordano may publish in the future.
Co-authorship network of co-authors of Sharon H. Giordano
This figure shows the co-authorship network connecting the top 25 collaborators of Sharon H. Giordano. A scholar is included among the top collaborators of Sharon H. Giordano based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sharon H. Giordano. Sharon H. Giordano is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Sullivan, M. P., et al.. (2025). Use of adjuvant capecitabine in older patients with early-stage triple-negative breast cancer. Breast Cancer Research and Treatment. 211(1). 213–221.
2.
Lei, Xiudong, Chi‐Fang Wu, Hui Zhao, et al.. (2024). Utilization of Biologic Disease‐Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer. Arthritis Care & Research. 76(6). 850–859.
3.
Zhao, Hui, et al.. (2024). Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 2021. Breast Cancer Research and Treatment. 210(1). 191–203.
4.
Diao, Kevin, Xiudong Lei, Weiguo He, et al.. (2023). Racial and Ethnic Differences in Long-Term Adverse Radiation Therapy Effects Among Breast Cancer Survivors. International Journal of Radiation Oncology*Biology*Physics. 118(3). 626–631.
5.
Corrigan, Kelsey L., Ramez Kouzy, Joseph Abi Jaoude, et al.. (2022). Inclusion of premenopausal women in breast cancer clinical trials. The Breast. 66. 204–207.
6.
Giordano, Sharon H., Maria Alice Franzoi, Sarah Temin, et al.. (2022). Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2612–2635.
7.
Ramakrishna, Naren, Carey K. Anders, Nancy U. Lin, et al.. (2022). Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update. Journal of Clinical Oncology. 40(23). 2636–2655.
8.
Lu, Huifang, Xiudong Lei, Hui Zhao, et al.. (2020). Bone Mineral Density at the Time of Initiating Aromatase Inhibitor Therapy Is Associated With Decreased Fractures in Women With Breast Cancer. Journal of Bone and Mineral Research. 36(5). 861–871.
9.
Hoover, Diana S., Monique R. Pappadis, Ashley J. Housten, et al.. (2018). Preferences for Communicating about Breast Cancer Screening Among Racially/Ethnically Diverse Older Women. Health Communication. 34(7). 702–706.
10.
Burstein, Harold J., Christina Lacchetti, Holly Anderson, et al.. (2018). Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology. 37(5). 423–438.
11.
Nelson, David B., David C. Rice, Jiangong Niu, et al.. (2017). Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. Journal of Clinical Oncology. 35(29). 3354–3362.
12.
Chávez‐MacGregor, Mariana, Elizabeth A. Mittendorf, Christina A. Clarke, et al.. (2017). Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System. The Oncologist. 22(11). 1292–1300.
13.
Giordano, Sharon H., Sarah Temin, Jeffrey J. Kirshner, et al.. (2014). Systemic Therapy for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology. 32(19). 2078–2099.
14.
Murthy, Rashmi K., Ankur Varma, Kenneth R. Hess, et al.. (2014). Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2‐positive metastatic breast cancer. Cancer. 120(13). 1932–1938.
15.
Guadagnolo, B. Ashleigh, Kai-Ping Liao, Linda S. Elting, et al.. (2012). Use of Radiation Therapy in the Last 30 Days of Life Among a Large Population-Based Cohort of Elderly Patients in the United States. Journal of Clinical Oncology. 31(1). 80–87.
16.
Smith, Benjamin D., Jing Jiang, Arti Hurria, et al.. (2011). Improvement in Breast Cancer Outcomes Over Time: Are Older Women Missing Out?. Journal of Clinical Oncology. 29(35). 4647–4653.
17.
Shih, Ya‐Chen Tina, Ying Xu, Janice N. Cormier, et al.. (2009). Incidence, Treatment Costs, and Complications of Lymphedema After Breast Cancer Among Women of Working Age: A 2-Year Follow-Up Study. Journal of Clinical Oncology. 27(12). 2007–2014.
18.
Fang, Shenying, et al.. (2009). Impact of Diabetes Mellitus on Complications and Outcomes of Adjuvant Chemotherapy in Older Patients With Breast Cancer. Journal of Clinical Oncology. 27(13). 2170–2176.
19.
Buzdar, Aman U., Nuhad K. Ibrahim, Daniel J. Booser, et al.. (2005). Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer. Journal of Clinical Oncology. 23(16). 3676–3685.
20.
Hennessy, Bryan T., Savitri Krishnamurthy, Sharon H. Giordano, et al.. (2005). Squamous Cell Carcinoma of the Breast. Journal of Clinical Oncology. 23(31). 7827–7835.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Hyman B. Muss Breakdown of academic impact, for papers by William F. Anderson Breakdown of academic impact, for papers by J.W.W. Coebergh Breakdown of academic impact, for papers by Mark R. Somerfield Breakdown of academic impact, for papers by Alan S. Coates Breakdown of academic impact, for papers by Harold J. Burstein Breakdown of academic impact, for papers by Roger A’Hern Breakdown of academic impact, for papers by Michael Friedländer Breakdown of academic impact, for papers by Antonio C. Wolff Breakdown of academic impact, for papers by Lynn A. G. Ries